2024
EP.06D.04 Prognostic Value of Variant Allele Frequency in Circulating Tumor DNA for Survival Outcomes in Metastatic Non-Small Cell Lung Cancer
Peleg A, de la Fuente R, Lichtman S, Gomez J, Doroshow D, Hirsch F, Veluswamy R, Marron T, Rohs N, Smith C, Rolfo C. EP.06D.04 Prognostic Value of Variant Allele Frequency in Circulating Tumor DNA for Survival Outcomes in Metastatic Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2024, 19: s502-s503. DOI: 10.1016/j.jtho.2024.09.932.Peer-Reviewed Original ResearchP3.06D.04 Role of ctDNA Variant Allele Frequency in Predicting Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
de la Fuente R, Peleg A, Litchman S, Gomez J, Doroshow D, Hirsch F, Veluswamy R, Marron T, Smith C, Rohs N, Rolfo C. P3.06D.04 Role of ctDNA Variant Allele Frequency in Predicting Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2024, 19: s323. DOI: 10.1016/j.jtho.2024.09.579.Peer-Reviewed Original ResearchAn updated comparative analysis of needs and role of patient navigation among early phase cancer clinical trial participants and non-participants at a single cancer center.
Doroshow D, Sheng T, Aryeh B, Conner R, Loehle J, Lucas N, Padilla M, Pappalardo R, Fromm K, Smith C. An updated comparative analysis of needs and role of patient navigation among early phase cancer clinical trial participants and non-participants at a single cancer center. Journal Of Clinical Oncology 2024, 20: 237-237. DOI: 10.1200/op.2024.20.10_suppl.237.Peer-Reviewed Original ResearchSDoH barriersEarly phase clinical trialsCancer clinical trial participationSocial drivers of healthDrivers of healthHealth care systemClinical trial participationClinical trialsPatient navigationFinancial toxicitySDoHSymptom burdenCare systemImprove participationNeeds assessmentDiagnosis to treatmentDescriptive characteristicsPhase clinical trialsTrial participantsLevel of acceptanceLonger visitsVulnerable populationsNon-participantsTreatment adherenceScreening visit632P Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors
Lin C, Schneider R, Gutierrez M, Shen L, Chung K, Doroshow D, Gao B, Millward M, Hsieh C, Xu C, Cai S, Tian Y, Liu L, Shen C, Tan Y, He Y, Zhang C, Li L, Ma M, Xu L. 632P Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors. Annals Of Oncology 2024, 35: s503-s504. DOI: 10.1016/j.annonc.2024.08.699.Peer-Reviewed Original ResearchPeripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis
Karol A, Fujiwara Y, D'Ovidio T, Baldwin E, Joshi H, Doroshow D, Galsky M. Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis. Immunotherapy 2024, 16: 829-840. PMID: 39155854, PMCID: PMC11457654, DOI: 10.1080/1750743x.2024.2379230.Peer-Reviewed Original ResearchImmune checkpoint blockadeProgression-free survivalC-reactive proteinPeripheral blood cytokinesOverall survivalTumor-promoting inflammationCheckpoint blockadeInterleukin-6Interleukin-8Blood cytokinesOn-treatment declineIL-8 levelsTrial end pointsIL-6 levelsPharmacodynamic biomarkersInflammatory cytokinesEnd pointsResponse rateCytokinesMeta-analysisSystematic reviewBlockadeInflammationORRSurvivalA comparative analysis of needs and role of patient navigation among early-phase cancer clinical trial participants and non-participants at a single cancer center.
Doroshow D, Sheng T, Aryeh B, Conner R, Loehle J, Lucas N, Padilla M, Pappalardo R, Fromm K, Smith C. A comparative analysis of needs and role of patient navigation among early-phase cancer clinical trial participants and non-participants at a single cancer center. Journal Of Clinical Oncology 2024, 42: e23127-e23127. DOI: 10.1200/jco.2024.42.16_suppl.e23127.Peer-Reviewed Original ResearchSDoH barriersEarly phase clinical trialsCancer clinical trial participationSocial drivers of healthDrivers of healthHealth care systemClinical trial participationPatient navigationNavigation interventionClinical trialsFinancial toxicityIdentified barriersCare systemSDoHImprove participationNeeds assessmentDiagnosis to treatmentDescriptive characteristicsTrial participantsLevel of acceptanceVulnerable populationsNon-participantsPhase clinical trialsTreatment adherenceScreening visitTrastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02).
Oh D, Lugowska I, Stroyakovskiy D, Jung K, Dumas O, Penkov K, Dechaphunkul A, Oaknin A, Kim S, Starling N, Chewaskulyong B, Charonpongsuntorn C, Doroshow D, Hsiao S, Hung Y, Jung L, Kuptsova-Clarkson N, Michelini F, Puvvada S, Meric-Bernstam F. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02). Journal Of Clinical Oncology 2024, 42: 4090-4090. DOI: 10.1200/jco.2024.42.16_suppl.4090.Peer-Reviewed Original ResearchBiliary tract cancerProgression-free survivalT-DXdPancreatic cancerHER2 expressionEfficacy outcomesDrug-related interstitial lung diseaseOpen-label phase 2 studyPC cohortDrug-related adverse eventsLate-line treatmentPrimary tumor locationPhase 2 studyGrade (GClinically meaningful benefitInterstitial lung diseaseHER2-expressing tumorsAdvanced/metastatic diseaseData cutoffIHC 3PD-L1Trastuzumab deruxtecanExploratory endpointsTumor locationPrimary endpointEfficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study.
Wysocki P, Jung K, Oh D, Doroshow D, Artamonova E, Mammatas L, SU P, Moiseyenko V, Penkov K, Stroyakovskiy D, Bartolome J, Siena S, Fielding A, Jung L, Michelini F, Puvvada S, Makker V. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study. Journal Of Clinical Oncology 2024, 42: 4565-4565. DOI: 10.1200/jco.2024.42.16_suppl.4565.Peer-Reviewed Original ResearchDisease control rateProgression-free survivalDuration of responseT-DXdPretreated ptsHER2 expressionUrothelial cancerBladder cohortEfficacy outcomesSolid tumorsSafety of trastuzumab deruxtecanDrug-related adverse eventsPhase 2 studyClinically meaningful responseGrade (GHER2 expression levelsTrastuzumab deruxtecanAdvanced/metastatic diseaseData cutoffPD-L1Open-labelExploratory endpointsPrimary endpointSystemic treatmentSecondary endpointsOptimizing care in early phase cancer trials: The role of palliative care
Crowley F, Sheppard R, Lehrman S, Easton E, Marron T, Doroshow D, Afezolli D. Optimizing care in early phase cancer trials: The role of palliative care. Cancer Treatment Reviews 2024, 128: 102767. PMID: 38776612, DOI: 10.1016/j.ctrv.2024.102767.Peer-Reviewed Original ResearchPalliative care interventionsPalliative careCare interventionsSymptom managementUnique palliative care needsPalliative care needsPalliative care workforcePhysical symptom managementPalliative care approachAdvance care planningHome-based interventionClinical trial participationPsychological well-beingCare planningCare workforceCare needsCare utilizationCare approachSpiritual supportOptimal careIncreased length of timeTrial participantsIntervention studiesEarly phase clinical trialsCareC-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis
Fujiwara Y, Karol A, Joshi H, Reford E, Izadmehr S, Doroshow D, Galsky M. C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis. Critical Reviews In Oncology/Hematology 2024, 197: 104352. PMID: 38614269, PMCID: PMC11219184, DOI: 10.1016/j.critrevonc.2024.104352.Peer-Reviewed Original ResearchConceptsProgression-free survivalC-reactive proteinUrothelial carcinomaTumor-promoting inflammationOverall survivalCRP valuesHazard ratioPro-inflammatory tumor microenvironmentAssociated with shorter OSICB-treated patientsImmune checkpoint blockadeEvaluate survival outcomesRandom-effects model meta-analysesHigher CRP levelsSystematic reviewMeta-analysesLow CRP valuesCheckpoint blockadeShorter OSSurvival outcomesTumor microenvironmentCRP levelsPrognostic biomarkerCarcinomaPatients
2023
An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis
LaMarche N, Hegde S, Park M, Maier B, Troncoso L, Le Berichel J, Hamon P, Belabed M, Mattiuz R, Hennequin C, Chin T, Reid A, Reyes-Torres I, Nemeth E, Zhang R, Olson O, Doroshow D, Rohs N, Gomez J, Veluswamy R, Hall N, Venturini N, Ginhoux F, Liu Z, Buckup M, Figueiredo I, Roudko V, Miyake K, Karasuyama H, Gonzalez-Kozlova E, Gnjatic S, Passegué E, Kim-Schulze S, Brown B, Hirsch F, Kim B, Marron T, Merad M. An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis. Nature 2023, 625: 166-174. PMID: 38057662, PMCID: PMC11189607, DOI: 10.1038/s41586-023-06797-9.Peer-Reviewed Original ResearchConceptsInterleukin-4IL-4RαMyeloid cellsCheckpoint blockadeTumor burdenPD-1/PD-L1 checkpoint blockadePD-1/PD-L1 blockadeBone marrowTumor-infiltrating CD8 T cellsType 2 cytokines interleukin-4PD-L1 checkpoint blockadeCell lung cancer lesionsNon-small cell lung cancer lesionsDepletion of basophilsPD-L1 blockadePrimary disease siteCD8 T cellsImmune checkpoint blockadeLung cancer lesionsNovel combination therapiesCytokine interleukin-4Bone marrow basophilsConditional knockout miceRefractory NSCLCEarly myeloid progenitorsA case of urticarial vasculitis associated with atezolizumab
Young J, Rivera-Oyola R, Poplausky D, Suemitsu Y, Kim R, Doroshow D, Gulati N. A case of urticarial vasculitis associated with atezolizumab. JAAD Case Reports 2023, 43: 30-33. PMID: 38162407, PMCID: PMC10757233, DOI: 10.1016/j.jdcr.2023.09.042.Peer-Reviewed Original ResearchEP12.01-10 Predictors of Poor Outcomes Among Patients Receiving 1st-Line Osimertinib for Advanced EGFR Mutated Non-Small Cell Lung Cancer
Desland F, Fitzgerald B, Sheppard R, Van Hyfte G, Shimkus M, Rohs N, Veluswamy R, Rolfo C, Marron T, Smith C, Gomez J, Doroshow D. EP12.01-10 Predictors of Poor Outcomes Among Patients Receiving 1st-Line Osimertinib for Advanced EGFR Mutated Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2023, 18: s644. DOI: 10.1016/j.jtho.2023.09.1225.Peer-Reviewed Original ResearchcfDNA NGS for Identification of Primary and Acquired Resistance in Patients With Lung Cancer and EGFR Mutations
Peleg A, Del Re M, Raphael A, Wang X, Berkovich A, Tsuriel S, Lichtman S, Elias E, Gomez J, Doroshow D, Smith C, Veluswamy R, Marron T, Rohs N, Mack P, Hirsch F, Rolfo C. cfDNA NGS for Identification of Primary and Acquired Resistance in Patients With Lung Cancer and EGFR Mutations. The Journal Of Liquid Biopsy 2023, 1: 100047. DOI: 10.1016/j.jlb.2023.100047.Peer-Reviewed Original ResearchThe past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas
Offin M, Fitzgerald B, Zauderer M, Doroshow D. The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas. Journal Of Cancer Metastasis And Treatment 2023, 9: null-null. PMID: 38895597, PMCID: PMC11185317, DOI: 10.20517/2394-4722.2022.140.Peer-Reviewed Original ResearchDiffuse pleural mesotheliomaPleural mesotheliomaClinical trialsAvailability of preclinical modelsSuppressor T cell activityRefining patient selection criteriaWilms' tumor 1 proteinBRCA1-associated protein 1Vascular endothelial growth factorT cell activationPatient selection criteriaTargeted therapeutic strategiesEndothelial growth factorTargeted therapeutic approachesClinically relevant biomarkersArgininosuccinate synthetase 1Preclinical dataTargeted therapyPreclinical modelsMethylthioadenosine phosphorylaseTherapeutic strategiesTherapeutic approachesRelevant biomarkersGrowth factorGenomic landscape
2017
Trastuzumab emtansine: determining its role in management of HER2+ breast cancer
Doroshow DB, LoRusso PM. Trastuzumab emtansine: determining its role in management of HER2+ breast cancer. Future Oncology 2017, 14: 589-602. PMID: 29214842, DOI: 10.2217/fon-2017-0477.Peer-Reviewed Original ResearchConceptsBreast cancerAnti-HER2 monoclonal antibody trastuzumabManagement of HER2Single-agent trastuzumabTumor-directed cytotoxicityAcceptable toxicity profileFirst-line treatmentPhase III trialsMonoclonal antibody trastuzumabAdjuvant managementIII trialsOverall survivalAdvanced HER2Cardiac toxicityTrastuzumab emtansineAgent trastuzumabToxicity profileAntibody trastuzumabSystemic toxicityHER2CancerTrastuzumabStable linkerOngoing studiesToxicityBET inhibitors: a novel epigenetic approach
Doroshow DB, Eder JP, LoRusso PM. BET inhibitors: a novel epigenetic approach. Annals Of Oncology 2017, 28: 1776-1787. PMID: 28838216, DOI: 10.1093/annonc/mdx157.Peer-Reviewed Original ResearchConceptsBET inhibitorsHDAC inhibitorsEpigenetic agentsExtra-terminal motif (BET) proteinsImmune checkpoint inhibitorsEarly clinical trialsNovel epigenetic approachHistone deacetylaseZeste homolog 2BET proteinsMonotherapy activityCheckpoint inhibitorsTargeted agentsPreclinical dataClinical trialsDrug classesDrug combinationsSingle agentSolid tumorsPreclinical researchTumor cellsHomolog 2Lysine-specific demethylase 1Anticancer therapyInhibitors- "A history of child psychiatry." In Lewis's Child and Adolescent Psychiatry, 5th edition, eds. Andrés Martin, Fred R. Volkmar, and Michael H. Bloch (Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2017)Peer-Reviewed Original Research
2016
Residential Treatment and the Invention of the Emotionally Disturbed Child in Twentieth-Century America
Doroshow DB. Residential Treatment and the Invention of the Emotionally Disturbed Child in Twentieth-Century America. Bulletin Of The History Of Medicine 2016, 90: 92-123. PMID: 27040027, DOI: 10.1353/bhm.2016.0023.Peer-Reviewed Original Research
2012
Matthew Smith, An Alternative History of Hyperactivity: Food Additives and the Feingold Diet
Doroshow D. Matthew Smith, An Alternative History of Hyperactivity: Food Additives and the Feingold Diet. Social History Of Medicine 2012, 25: 884-885. DOI: 10.1093/shm/hks043.Peer-Reviewed Original Research